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ABSTRACT - Purpose. Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by 
the loss of motorneurons. The only drug approved is riluzole. Minocycline is an antibiotic with numerous 
neuroprotective properties. riluzole and minocycline were given to an animal model of ALS and had 
beneficial effect on the disease. The combination was then tested in humans in phase II and phase III studies 
with less beneficial effects and a faster decline of the disease in the group treated with minocycline. In a 
previous study, we showed that riluzole is transported out of the brain by the P-glycoprotein at the blood-
brain barrier level. In this work, we tested the hypothesis of a drug-drug interaction between riluzole and 
minocycline. Methods. We studied in CF1 mice, the plasma and brain pharmacokinetics of riluzole 
combined or not with minocycline. Results. Our results showed that riluzole pharmacokinetics are not linear 
with dose, but that brain AUC0-t increase proportionally with plasma AUC0-t. At the dose of 10 mg/kg, the 
brain AUC0-t /plasma AUC0-t ratio was 4.6 in mdr1a (-/-) mice and 2.4 in mdr1a (+/+) mice. The 
combination of minocycline (170 mg/kg) and riluzole (10 mg/kg) induced a 2 fold increase in the brain 
AUC0-t of riluzole and induced a neuromuscular toxicity in mice. This effect of minocycline was not found 
at low concentration (10 mg/kg of minocycline). Conclusions. If our results are confirmed in humans, 
riluzole brain concentrations could be predicted by plasma concentrations. Furthermore, the combination of 
high doses of minocycline with riluzole could induce neurological toxicity that lead to deceiving results in 
ALS clinical studies. Hence, a dose-range of minocycline combined with riluzole should be tested in further 
clinical studies. 
 
INTRODUCTION 
 
Amyotrophic lateral sclerosis (ALS) is a fatal 
neurodegenerative disease characterized by 
progressive muscle weakness, muscle atrophy and 
paralysis (1-3). Riluzole is currently the only 
approved pharmacological treatment of ALS (4, 
5). However, the clinical outcome of this 
compound is very modest. In recent studies, 
minocycline, a tetracyclic antibiotic, exhibited 
neuroprotective properties that led to preclinical 
and clinical studies (6-8). 
In a mice model of ALS, the combination 
of minocycline, riluzole and creatine had 
beneficial effects on the disease progression and 
survival of mice (9). However, like many other 
molecules, after interesting results in animal 
studies, its efficacy was very limited in humans. 
In ALS patients, clinical trials testing minocycline 
(alone or in combination), were conducted in order 
to improve the efficacy of the treatment (10). 
Minocycline was first evaluated in pilot phase II  
 
 
studies in small groups of ALS patients (11). 
These trials were designed to test (1) the safety 
and tolerability of different doses of minocycline 
over prolonged periods in subjects taking riluzole 
and (2) doses of minocycline higher than the ones 
previously given, attempting to obtain the highest 
tolerable dosage. These trials were realised as 
feasibility studies for a larger phase III trial of 
efficacy. A multicenter randomized controlled 
trial was then conducted to establish the efficacy 
of minocycline in patients with ALS (10). This 
study is one of the first randomized controlled 
trials which test the efficacy of minocycline in 
patients with a neurological disorder. 
________________________________________ 
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In this study, minocycline had a harmful effect on 
the course of ALS: Patients had a decline in the 
ALSFRS-R score used to assess the effect of the 
drug. A dose higher than the usual clinical dose 
was given, but authors concluded that the 
outcome was not related to dose, adverse effects 
or interaction with riluzole. Like other recent 
trials in which drugs had no benefit or seemed to 
cause deterioration in patients with ALS, possibly 
owing to interactions between the drugs and 
riluzole or adverse events, this trial could not 
replicate in patients the positive findings from 
laboratory studies. In this study, interpretation of 
the results did not include any pharmacokinetic 
data or argument. Leigh et al. have suggested that 
either high minocycline doses were responsible 
for the toxic effects observed, or an interaction 
occurred between riluzole and minocycline at the 
blood-brain barrier (BBB) level, leading to 
increased brain concentrations of riluzole (12). 
Our paper addresses this last issue, testing the 
interaction between riluzole and minocycline at the 
BBB level. 
The BBB restricts entry to the brain of 
xenobiotics because of very low paracellular 
(tight junctional) permeability and expression of 
potent multispecific efflux transporters. Together, 
they limit entry and thus efficiency of drugs 
targeted to brain diseases. Some efflux proteins (ABC 
or ATP Binding Cassette transporters) are expressed 
on the luminal membrane and are responsible for the 
extrusion of their substrates from the endothelial 
cells of the BBB back to the blood circulation (13, 
14). In previous studies, we have tested 
interactions between minocycline, riluzole and the 
efflux pumps at the BBB level. We showed 
mainly that P-glycoprotein (P-gp), the most 
influent efflux transporter at the BBB level, 
effluxes minocycline and riluzole out of the brain 
back to blood. We also showed that minocycline 
could inhibit P-gp functionality (15). Our results 
combined with Gordon’s study aroused the 
question of a potential pharmacokinetic drug-drug 
interaction between riluzole and minocycline that 
could prevent the beneficial effect of this drug 
combination. 
In order to explore this interaction, we 
have performed a complete brain and plasma 
pharmacokinetic study of riluzole, combined or 
not with minocycline, in mice. We have also 
performed a rotarod test to study the effect of 
riluzole and minocycline combination on 
neuromuscular function.     
 
 
METHODS 
 
Animals 
 
Female CF1 mdr1a (+/+) and CF1 mdr1a (-/-) 
mice (naturally defective in BBB P-gp) of 30-40 g 
were purchased from Charles River Laboratories 
(Wilmington, MA, USA). Mice had water and 
regular rodent chow. Animal manipulation 
followed current European Union regulations and 
all experiments were approved by an animal 
ethics committee. Mice were anesthetized with 
isoflurane and blood was collected by intracardiac 
puncture. After euthanasia, brains were collected 
and rinsed with NaCl 0.9% for further analysis. 
Plasmas and brains were stored at -80 oC for 
further analysis. 
 
Reagents 
 
Minocycline (minocycline hydrochloride) and 
riluzole were provided by Sigma-Aldrich (Saint 
Quentin Fallavier, France). All the reagents used 
are of analytical and/or HPLC quality 
 
Preparation of the solutions 
 
-Solutions for HPLC analysis 
Stock solutions of riluzole were prepared at 1 
mg/ml in Methanol:Water (50:50, v/v). Solutions 
were stored at -20°C and were stable for at least 3 
months. 
 
-Solutions for animal treatment 
For animal treatment, minocycline was dissolved 
in water and riluzole in Water:PropyleneGlycol 
(50:50, v/v). Doses used to treat animals in our 
study were similar to those used in previous 
animal studies where riluzole and minocycline 
showed interesting pharmacological properties in 
ALS mice (16, 17).   
 
High performance liquid chromatographic 
analysis 
 
The HPLC system consisted of a 715 UltraWisp 
autosample injector (Waters, StQuentin en 
Yvelines, France), a Shimadzu® LC-10AS pump 
and a Shimadzu® UV detector (Shimadzu, Croissy-
Beaubourg, France). Separation was achieved at 
room temperature on a reversed-phase Symmetry 
Shield 5 µm RP8 column (250 x 3 mm, i.d.) 
equipped with a Symmetry Shield 5 µm RP8 
precolumn (Waters, St-Quentin en Yvelines, 
France). The method was linear over the following 
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ranges: 0.1 - 4 µg/mL in plasma and 0.5 - 20 
µg/mg in brain. Intra-day and inter-day variabilities 
were always under 20%. Inaccuracies were under 
10%. Recoveries were 80 % in plasma and 75 % in 
brain. 
Riluzole was quantified in blood and 
brain using an HPLC/UV detection method 
already described in a previous study (18). 
Brain concentrations were corrected in order to 
consider vascular concentrations in the brain, as 
in previous study (15). 
 
Brain and plasma pharmacokinetics of riluzole 
in CF1 mdr1a (+/+) mice  
 
CF1 mdr1a (+/+) mice were divided into 3 groups 
(5, 10 or 20 mg/kg of riluzole; 27 mice/group). 
They were given a single dose of riluzole by 
intraperitoneal route (i.p.).  Blood and brain were 
collected at 0, 5, 10, 15, 30, 45, 60, 90 and 180 
minutes after injection. 
 
Brain and plasma pharmacokinetics of riluzole 
in CF1 mdr1a (-/-) mice 
 
27 CF1 mdr1a (-/-) mice were given a single dose 
of riluzole (10 mg/kg) by intraperitoneal route 
(i.p.).  Blood and brain were collected at 0, 5, 10, 
15, 30, 45, 60, 90 and 180 minutes after injection. 
 
Brain and plasma pharmacokinetics of riluzole 
when given with minocycline to CF1 mdr1a 
(+/+) mice  
CF1 mdr1a (+/+) mice were divided into 4 groups 
(27 mice/group) receiving 10 mg/kg of riluzole 
with 0, 10, 90 or 170mg/kg of minocycline. Blood 
and brain were collected at at 0, 5, 10, 15, 30, 45, 
60, 90 and 180 minutes after riluzole injection. 
 
 Evaluation of neuromuscular toxicity of 
riluzole/minocycline combination  
 
24 mice were divided into 3 groups (8 mice per 
group) and they were treated for five days with 
riluzole (10mg/kg) or minocycline (170 mg/kg) or 
both. Motor impairment was evaluated the day 6 
using the rotarod test. Each mouse was placed on 
a rod rotating at 16 rpm. The test began by 
training each mice 3 times for 1 minute each 10 
minutes. 1 hour after the training session, mice 
received riluzole (10 mg/kg), 25 minutes later 
they were put on the rod. The time the mouse 
stayed on the rod until it fell off (during a 3 
minutes interval) was recorded. Five minutes after 
the test (30 minutes after the injection), mice were 
killed. Blood and brain were collected for riluzole 
analysis.  
 
DATA ANALYSIS 
 
Maximun plasma concentrations (Cmax), times to 
reach maximum plasma concentrations (Tmax) 
and AUCs of average profiles were used for 
comparisons between mdr1a (-/-) and mdr1a (+/+) 
animals. Cmax and Tmax were determined by 
visually inspecting the experimental data. AUCs 
were estimated by the trapezoidal rule for the n-1 
subintervals from 0 to the last time point. We 
used the sample mean as the function height at the 
different time points. 
To study the potential correlation between 
brain AUC and plasma AUC as well as between 
riluzole brain concentrations and time spent on 
the rod, we used the Pearson product-moment 
correlation method. 
The method developed by Bailer for destructive 
sampling was used to compare the AUCs between 
the 
two treatment groups [2]. The standard error of 
the mean concentrations yi at time ti , denoted 
semi, was estimated as the empirical standard 
deviation divided by ri. Thus, the standard error of 
the mean AUC was estimated according to the 
equation: 
 
 
 
 
 
The test for equality of the mean AUCs between 
treatments A and B was performed using the 
standard Wald statistic: 
 
 
 
 
 
Under the null hypothesis that the mean AUCs are 
equal, this statistic follows a normal distribution. 
The null hypothesis was rejected if |zobs| was 
greater than 1.96. 
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RESULTS 
 
Brain and plasma pharmacokinetics of riluzole 
in CF1 mdr1a (+/+) mice 
 
Plasma and brain kinetic profiles were similar for 
the three doses of riluzole tested (5, 10 and 20 
mg/kg). Intracerebral entry of riluzole was rapid 
(tmax 5-30 minutes in brain and plasma) and was 
directly dependant on plasma concentration 
(Figure 1). Riluzole was not detectable in both 
tissues after 24 hours. The relations between 
plasma and brain AUCs is shown in Figure 2, for 
each dose, in mdr1a (+/+) and mdr1a (-/-) mice. 
The ratio plasma AUC0-t/Dose was significantly 
different between the three doses of riluzole, 
showing a non-linearity of the relation between 
AUC0-t and the dose. The Pearson correlation 
showed that plasma and brain AUC0-t were 
correlated for the three tested doses of riluzole (R2 
= 0.99, p <0.001) (Figure 3). Five minutes after 
high dose (20 mg/kg) injection of riluzole, 
animals exhibited adverse events such as posterior 
members paralysis, weakness and shaking. 
Pharmacokinetics parameters of riluzole are 
presented in Table 1. 
 
 
Figure 1. Plasma and brain pharmacokinetic profiles of riluzole given by i.p. route to CF1 mdr1a (+/+) mice 
(10mg/kg ; n=3 mice per time, m±sd). (brain concentration (round shape) in µg/g and plasma concentration (square 
shape) in µg/ml). 
 
Figure 2. Brain and plasma AUC 0-∞ obtained after administration of riluzole (5,10, 20 mg/kg) by i.p. route to CF1 
mdr1a (+/+) mice and at 10 mg/kg by i.p. route to CF1 mdr1a (-/-) mice (n= 27 mice/dose) (Brain AUC 0-∞ (white 
shape) and plasma AUC 0-∞  (black shape)). 
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Figure 3. Correlation Scatter plot of brain AUC and plasma AUC for the three tested doses of riluzole (5,10, 20 mg/kg) 
 
Table 1. Plasma and brain pharmacokinetic parameters of riluzole in CF1 mdr1a(+/+) and mdr1a(-/-) mice after i.p. 
administration of different doses of riluzole (n= 27 mice per dose) 
 
  
CF1 mdr1a (+/+) mice  CF1 mdr1a (-/-) mice 
5mg/kg 10mg/kg 20mg/kg  10mg/kg 
 
 
Plasma 
Cmax (µg/ml) 1 3 6  8 
Tmax (min) 15 60 45  10 
AUC0-t  (µg/ml*min) 212 800 2740  1824 
 
 
Brain 
Cmax (µg/g) 4 12 25  30 
Tmax (min) 10 10 30  10 
AUC0-t  (µg/g*min) 588 1957 5860  8508 
 
Brain and plasma pharmacokinetics of riluzole 
in CF1 mdr1a (-/-) mice 
 
Pharmacokinetic parameters for CF1 mdr1a (-/-) 
are presented in Table 1. Plasma AUC0-t, brain 
AUC0-t and brain / plasma AUC0-t ratio were 
higher in CF1 mdr1a (-/-) mice when compared to 
CF1 mdr1a (+/+) mice (p<0.05) (Figure 2). The 
brain /plasma AUC0-t ratio was 4.6 in mdr1a (-/-) 
mice and 2.4 in mdr1a (+/+) mice. 
Mdr1a (+/+) mice treated with 20 mg/kg 
and mdr1a (-/-) mice treated with 10 mg/kg 
experienced same neurological adverse events 
that included: tremor, weakness and temporary 
member paralysis. 
 
Brain and plasma pharmacokinetics of riluzole 
when given with minocycline in CF1 mdr1a 
(+/+) mice 
 
When combined with minocycline at 10 mg/kg, 
no significant modification of riluzole brain 
pharmacokinetic parameters was observed. 
Conversely, when given with 90 and 170 mg/kg 
of minocycline, brain/plasma AUC0-t ratio of 
riluzole was significantly increased by 1.7 and 2.0 
fold. Plasma riluzole AUC0-t was not 
significantly different between the four groups 
(Figure 4). Pharmacokinetics parameters of 
riluzole are presented in Table 2. 
 
Neuromuscular toxicity evaluation of 
riluzole/minocycline combination 
 
Motor impairment following mice treatment with 
riluzole/minocycline combination versus riluzole 
or minocycline alone was evaluated using the 
rotarod test. We observed that: 
-Mice treated with riluzole alone stayed 
longer on the rod. 
-The time spent on the rod was not 
significantly different between mincocyline and 
riluzole/minocycline groups. Minocycline did not 
increase the effect of riluzole on neuromuscular 
strength.  
-The time spent on the rod was 
significantly decreased in the group treated for 5 
days with the riluzole/minocycline combination 
compared to the group that received riluzole 
alone. 
-The mean time spent on the rod per 
group was correlated with riluzole brain 
concentration (R2=0.99, p<0.0001) (Figure 5). 
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Figure 4. Brain and plasma AUC0-t of riluzole (10 mg/kg) when given by i.p. route with minocycline (0, 10, 90 or170 
mg/kg) during 5 days. 
 
Table 2. Plasma and brain pharmacokinetic parameters of riluzole (10mg/kg) when given with minocycline by i.p. 
route (n=27 mice per dose). 
 
  
Minocycline dose 
Placebo 10mg/kg 90mg/kg 170mg/kg 
 
 
Plasma 
Cmax (µg/ml) 2.5 2.9 2.7 2.3 
Tmax (min) 5 5 30 30 
AUC0-t 
(µg/ml*min) 591 615 744 750 
 
 
Brain 
Cmax (µg/g) 12.5 10.6 11.1 16.6 
Tmax (min) 5 30 15 30 
AUC0-t  
(µg/g*min) 1749 2512 2973 3440 
 
DISCUSSION 
 
The aim of this paper was to study the plasma and 
brain pharmacokinetics of riluzole in mice and to 
check the hypothesis of drug-drug interaction 
between riluzole and minocycline. This 
hypothesis could explain the negative results of a 
recent clinical study that combined riluzole and 
minocycline in ALS patients (10). 
We have showed in these experiments, that 
combining riluzole to minocycline can enhance 
riluzole brain distribution and could be associated 
with central toxicity. 
When given to mice, increasing doses of 
riluzole induced a non-proportional increase in 
plasma AUC0-t. This could be due to saturation 
of metabolism. As plasma and brain 
pharmacokinetic profiles were similar, brain 
penetration of riluzole seemed to be rapid and non 
saturable at observed plasma concentrations. We 
had previously reported elsewhere that riluzole  
 
 
 
brain distribution was dependent on P-gp activity 
(18). In this assay, the 2-fold increase of brain / 
plasma AUC0-t ratio in CF1 mdr1a (-/-) mice 
when compared to CF1 mdr1a (+/+) mice 
reconfirmed that P-gp transports riluzole out of 
the brain. P-gp plays a protective role of the brain 
against riluzole penetration: it does not 
completely stop riluzole from entering the brain 
but it prevents high toxic brain concentrations of 
riluzole. The absence of P-gp at the BBB level in 
mdr1a(-/-) mice increased riluzole brain 
penetration and induced neurotoxic effects (for a 
10 mg/kg dose of riluzole) similar to those 
induced by high doses of riluzole (20 mg/kg) in 
mdr1a (+/+) mice. We did not expect any 
difference in plasma AUC between mdr1a (-/-) 
and (+/+) animals as P-gp does not interfere on 
transperitoneal transport. However, plasma 
AUC0-t were increased in CF1 mdr1a(-/-) mice. 
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Figure 5. Rotarod test results and brain concentrations of riluzole after 5 day treatment of CF1 mdr1a (+/+) mice with 
10 mg/kg of riluzole, 170 mg/kg of minocycline or the combination riluzole/minocycline (m±sd; time spent on the rod 
(white shape) in seconds; riluzole brain concentration (black shape) in µg/g). 
 
 
This effect can be explained by a lower biliary 
excretion rate in P-gp deficient mice. This 
phenomenon was already reported by Kwei et al. 
who have reported that ivermectin and 
cyclosporin intestinal excretion are lower in 
mdr1a (-/-) animals (19). 
In wild-type mice, the increase of brain 
AUC0-t is proportional to plasma AUC0-t which 
means that efflux of riluzole is not saturated at the 
observed brain concentrations. Also, if 
pharmacological effect or toxicity of riluzole is 
correlated to brain concentrations in patients, 
plasma AUC0-t could be used to predict this brain 
concentrations and so efficacy or toxicity. 
Such an hypothesis is supported by the 
results of Bensimon and Siniscalchi et al who 
showed that adverse neurological effects of 
riluzole, such as drowsiness, weakness, dizziness, 
are dose-dependent and could be correlated to 
brain concentrations (20, 21). Hence, any factor 
that increases brain concentrations of riluzole 
(overdosage, drug-drug interactions) could induce 
riluzole neurotoxicity. In patients, the increase of 
riluzole dose from 100 mg to 200 mg increased 
the risk of adverse effects as nausea, asthenia and 
hepatic transaminase elevation (5). In our study, 
in CF1 mdr1a(+/+) mice, the increase of dose up 
to 20 mg/kg induced high brain concentrations 
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and toxic effects as ataxia, tremor, posterior limb 
paralysis. 
Our work supports the hypothesis of an 
interaction between riluzole and minocycline 
which led to the negative effects of 
riluzole/minocycline combination. In a previous 
study, we have already shown that minocycline 
inhibits P-gp at the BBB level and leads to brain 
accumulation of P-gp substrates such as riluzole 
(15). In this study, we observed that the 
combination of minocycline with riluzole 
increases this latter brain AUC0-t without 
modification of his plasma AUC0-t. This 2-fold 
increase of the brain/plasma AUC0-t ratio is 
equivalent to that observed in CF1 mdr1a (-/-) 
mice when compared to CF1 mdr1a (+/+) mice 
and so can be due to the inhibition of P-gp by 
minocycline. 
This effect of minocycline on riluzole 
brain penetration was only observed with high 
doses of minocycline (90 and 170 mg/kg) and not 
with the lowest dose (10 mg/kg). In humans, 
doses used are much less, around 6 mg/kg. 
Gordon et al (10) have used the maximum 
tolerated doses of minocycline (up to 400 
mg/day). Our assays showed that minocycline can 
be safe, giving no adverse effects by itself but can 
also enhance combined drug toxicity. However, 
Pontieri et al have shown that combined treatment 
with riluzole and minocycline at the dose of 100 
mg/day (much lower than the 400 mg/day dose 
tested in Gordon et al study (10)) did not induce 
significant side effects (22). 
Hence, clinical studies with minocycline doses 
lower than 400 mg/day should be performed 
before concluding definitively to treatment 
failure. 
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